Kazia Therapeutics Limited American Depositary Shares (KZIA)
Stock · NASDAQ · Health Care
$7.46as of 10/16/2026
Price chart
Active signals
KZIA Signal Track Record
How signals performed across all stocks →What KZIA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | +5.4% | 54% | September 15, 2026 |
| Bollinger Band Breakdown | 23 | -8.3% | 30% | June 3, 2026 |
| Bollinger Band Breakout | 19 | -3.5% | 42% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -4.4% | 33% | September 21, 2026 |
| Any 20-session window (baseline) | -8.0% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KZIA
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isoc…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- www.kaziatherapeutics.com/
Fundamentals
- 1-day range
- $6.8$7.59
- Market cap
- $140.89M
- P/E (trailing)
- —
- P/E (forward)
- -619.70
- EPS (trailing)
- $-0.02
- Dividend yield
- —
- Beta
- 2.37
- Avg. volume
- 274.9K
- Dividend pay date
- July 14, 2017
Forecasts
6 analyst ratings
Kazia Therapeutics Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- CNTNCanton Strategic Holdings Inc. Common Stock$1.7▼ 9.36%Market cap $143.45MP/E —$1.75$6.89
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- ADCTADC Therapeutics SA Common Shares$1.4▼ 6.04%Market cap $143.73MP/E —$0.7796$4.98
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $143.45M | — | $1.7 | ▼ 9.36% | $1.75$6.89 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| ADCT ADC Therapeutics SA Common Shares | $143.73M | — | $1.4 | ▼ 6.04% | $0.7796$4.98 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersYahoo · 9/22/2026
- Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat EpilepsiesBenzinga · 9/22/2026
- Bank of New York Mellon Corporation (BNY) Lost A Depositary MandateYahoo · 9/19/2026
- Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - SlideshowSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Levine James E. · June 19, 2026 · Grant200.0K
- Rao Sudha · June 19, 2026 · Grant250.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.75M
- Total value held
- $12.97M
- Institutional holders
- 23
- Unknown400.0K
- Unknown345.2K
- Unknown200.0K
- Unknown193.1K
- Unknown142.5K
- Unknown135.3K
- Unknown79.8K
- Unknown60.0K
- Unknown50.4K
- Unknown34.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial
Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial. Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.